The role of parathyroid hormone in the pathogenesis, prevention and treatment of postmenopausal osteoporosis

Aging Clinical and Experimental Research

Volumn 10, Issue 3, 1998, Pages 232-239

  Masiukiewicz, U S ^a   Insogna, K L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone loss; Bone remodeling; Osteoporosis; Parathyroid hormone

Indexed keywords

PARATHYROID HORMONE;

BONE DENSITY; BONE MASS; BONE REMODELING; GROWTH REGULATION; HORMONAL REGULATION; HORMONAL THERAPY; HUMAN; PATHOPHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; VITAMIN D METABOLISM;

EID: 0031665266     PISSN: 03949532     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03339657     Document Type: Review

References (61)

1. Eastell R., Cedel S., Wahner H., Riggs E., Melton L.: Classification of vertebral fractures. J. Bone Miner. Res. 6: 207-215, 1991.
2. Ettinger B., Black D., Nevitt M., Rundell A., Cauley J., Cummings S., Genant H.: The Study of osteoporotic fractures research group. Contribution of vertebral deformities to chronic back pain and disability. J. Bone Miner. Res. 7: 449-456, 1992.
3. Jones G., Nguyen T., Sambrook P., Kelly P., Eisman J.: Progressive loss of bone in the femoral neck in elderly people: longitudinal findings from the Dubbo osteoporosis epidemiology study. BMJ 309: 691-695, 1994
4. Parfitt A.M.: Osteonal and hemiosteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. J. Cell. Biochem. 55: 273-286, 1994.
5. Abu-Samra A.B., Juppner H., Force T.: Expression and cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol triphosphates and increases intracellular free calcium. Proc. Natl. Acad. Sci. USA 89: 2732-2736, 1992.
6. Lowik C.W., van der Pluijm G., Bloys H.: Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells; a possible role of interleukin-6 in osteoclastogenesis. Biochem. Biophys. Res. Commun. 162: 1546-1552, 1989.
7. Horowitz M., Brown M., Insogna K., Coleman D., Centrella M., Phillips J., Weir E.: PTHrP and PTH induce the secretion of IL-6 by a clonal osteosarcoma cell line. In: Oppenheim J.J., Powanda M.C., Kluger M.J., Dinarello C.A. (Eds.), Molecular and Cell Biology of Cytokines. Wiley-Liss, New York, 1990, pp. 471-476.
8. Li N., Ouchi Y., Okamoto Y., Okamato Y., Masayama A., Kaneki M., Futami A., Hosoi T., Nakamura T., Orimo H.: Effect of parathyroid hormone on release of interleukin 1 and interleukin 6 from cultured mouse osteoblastic cells. Biochem. Biophys. Res. Commun. 179: 236-242, 1991.
9. Greenfield E.M., Gomik S.A., Horowitz M C., Donahue H.J., Shaw S.M.: Regulation of cytokine expression in osteoblasts by parathyroid hormone: rapid stimulation of interleukin 6 and leukemia inhibitory factor mRNA. J. Bone Miner. Res. 8: 1163-1171, 1993.
10. Sakagami Y., Girasole G., Yu X-P., Boswell H.S., Manolagas S.C.: Stimulation of interleukin-6 production by either calcitonin gene-related peptide or parathyroid hormone in two phenotypically distinct bone marrow-derived murine stromal cell tines. J. Bone Miner. Res. 8: 811-816, 1993.
11. Onyia J.E., Bidwell J., Herring J., Hulman J., Hock J.M.: In vivo, human parathyroid hormone fragment (hPTH 1-34) transiently stimulates immediate early response gene expression, but not proliferation, in trabecular bone cells of young rats. Bone 17: 479-484, 1995.
12. Greenfield E M., Shaw S.M., Gornik S.A., Banks M.A.: Adenyl cyclase and IL-6 are downstream effectors of parathyroid hormone resulting in stimulation of bone resorption. J. Clin. Invest. 96: 1238-1244, 1995.
13. Grey A , Mitnick M., Manolagas S., Jilka R., Insogna K.: Interleukin-6 mediates PTH-induced bone resorption in vivo. J. Bone Miner. Res. 12 (Suppl. 1): S112, 1997.
14. McCarthy T.L., Centrella M., Canalis E.: Parathyroid hormone enhances the transcript and polypeptide levels of insulin-like growth factor I in osteoblast enriched cultures from fetal rat bone. Endocrinology 124: 1247-1253, 1989.
15. Linkhart T.A., Mohan S.: Parathyroid hormone stimulates release of insulin-like growth factor-I (IGF-I), IGF-II from neonatal mouse calvaria in organ culture. Endocrinology 125: 1484-1491, 1989.
16. McCarthy T.L., Centrella M., Canalis E.: Regulatory effects of insulin-like growth factors I and II on bone collagen synthesis in rat calvarial cultures. Endocrinology 124: 301-309, 1989.
17. Oursler M.J , Cortese C., Keeting P., Anderson M.A., Bonde S.K., Riggs L., Spelsberg T.C.: Modulation of transforming growth factor β production in normal human osteoblast-like cells by 17 β-estradiol and parathyroid hormone. Endocrinology 129: 3313-3320, 1991.
18. Bonewald L.F., Mundy G.R.: Role of transforming growth factor-beta in bone remodeling. Clin. Orthop. 250: 261-276, 1990.
19. Chenu C., Pfeilschifter J., Mundy G.R., Roodman G.D.: Transforming growth factor beta inhibits formation of osteoclast like-cells in long-term human marrow cultures. Proc. Natl. Acad. Sci. USA 85: 5683-5687, 1988.
20. Dempster D.W., Cosman F., Parisien M., Shen V., Lindsay R.: Anabolic actions of parathyroid hormone in bone. Endocr. Rev. 14: 690-709, 1993.
21. Hock J.M., Gera I.: Effects of continuous and intermittent administration and inhibition of the anabolic response of bone to parathyroid hormone. J. Bone Miner. Res. 7: 65-72, 1992.
22. Palmer M., Jakobsson S., Akertrom G., Ljunghall S.: Prevalence of hypercalcemia in a health survey: a 14-year follow-up study of serum calcium values. Eur. J. Clin. Invest. 18: 39-46, 1988.
23. Grey A.B.: The skeletal effects of primary hyperparathyroidism. In: Reid LR. (Ed.), Bailliere's Clin. Endocrinol. Metab. 11: 101-116, 1997
24. Grey A.B., Mitnick M.A., Shapses S., Ellison A., Gunberg C., Insogna K.L.: Circulating levels of interleukin-6 and tumor necrosis factor-a are elevated in primary hyperparathyroidism and correlate with markers of bone resorption. A clinical research center study. J. Clin. Endocrinol. Metab. 81: 3450-3454, 1996.
25. Dempster D W., Parisien M., Schnitzer M., Silverberg S.J., Shane E., Liang X.G., Shen V., Lindsay R., Bilezikian J.P.: Longitudinal study of bone structure and turnover in patients with primary hyperparathyroidism who undergo parathyroidectomy or are managed medically. J. Bone Miner. Res. 10 (S1): S505, 1995
26. Grey A.B., Stapleton J.P., Evans M.C., Reid I.R.: Accelerated bone loss in postmenopausal women with primary hyperparathyroidism. Clin. Endocrinol 44: 697-702, 1996.
27. Guo C-Y., Thomas W.E.G., Al-Dehaimi A.W., Assiri A M.A, Eastell R.: Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 81: 3487-3491,1996.
28. Silverberg S.J , Gartenberg F., Jacobs T.P., Shane E., Siris E., Staron R.B., Bilezikian J., Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 80: 723-728, 1995.
29. Insogna K., Ellison A., Gundberg C., Mitnick M.: Selective femoral neck osteopenia is a marker for secondary hyperparathyroidism. J. Bone Miner. Res. 11 (Suppl. 1): S445, 1996.
30. Riggs B.L., Gallagher J.C., DeLuca H.F., Edis A.J., Lambert P.W., Arnaud C.D : A syndrome of osteoporosis increased serum immunoreactive parathyroid hormone, and inappropriately low serum 1,25-dihydroxyvitamin D. Mayo Clin. Proc. 53: 701-706, 1978.
31. Baker M.R., Peacock M., Nordin B.E.C.: The decline in vitamin D status with age. Age Ageing 9: 249-252, 1980
32. Tsai K-S., Heath H., Kumar R., Riggs B.L.: Impaired vitamin D metabolism with aging in women: possible role in pathogenesis of senile osteoporosis. J. Clin. Invest. 73: 1668-1672, 1984.
33. Siovick D.M., Adams J.S., Neer R.M., Holick M.F., Potts J.T.: Deficient production of 1,25-dihydroxyvitamin D in elderly osteoporotic patients. N. Engl. J. Med. 305: 372-374, 1981.
34. Prince R.: Counterpoint: estrogen effects on calcitropic hormones and calcium homeostasis. Endo. Rev. 15: 301-309, 1994.
35. Fischer M., Fareley S., Ludi D., Baylink D.: Unexpected high prevalence of hyperparathyroidism in a large osteoporotic population. Bone 16 (Suppl. 1):1-30S, 1995.
36. Prince R.L., Dick I.M., Lemmon J., Randell D.: The pathogenesis of age-related osteoporotic fracture: effects of dietary calcium deprivation. J. Clin. Endocrinol. Metab. 82: 260-279, 1997.
37. Sakhaee K., Nicar M.J., Glass K., Pak C.Y.C.: Postmenopausal osteoporosis as a manifestation of renal hypercalciuria with secondary hyperparathyroidism. J. Clin. Endocrinol. Metab. 61: 368-373, 1985.
38. Khosla S., Atkinson E., Melton J., Riggs L : Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women: a population-based study. J. Clin. Endocrinol. Metab. 82: 1522-1527, 1997.
39. Cosman F., Shen V., Fang X., Seibel M., Ratcliffe A., Lindsay R.: Estrogen protection against bone resorbing effects of parathyroid hormone infusion: assessment by use of biochemical markers. Ann. Intern. Med. 118: 337-343, 1993.
40. Joborn C., Ljunghall S., Larsson K., Lindh E., Naessen T., Wide L., Akerstrom G., Rastad J.: Skeletal responsiveness to parathyroid hormone in healthy females: relationship to menopause and oestrogen replacement. Clin. Endocrinol. 34: 335-339, 1991.
41. Gamero P., Somey-Rendu E., Chapuy M-C., Delmas P.D.: Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J. Bone Miner. Res. 11: 337-349, 1996.
42. Ross P., Knowlton W.: Rapid bone loss is associated with increased levels of biochemical markers. J Bone Miner. Res. 13: 297-302, 1998.
43. Rosen C., Chestnut C., Mallinak N.: The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J. Clin. Endocrinol. Metab. 82: 1904-1910, 1997.
44. Whitfield J.F., Morley P., Ross V., Isaacs R.J., Rixon R.H.: Restoration of severely depleted femoral trabecular bone in ovariectomized rats by parathyroid hormone (1-34). Calcif. Tissue Int. 56: 227-231, 1995.
45. Uu C.C., Kalu D.N., Salerno E., Echon R., Hollis B.W., Ray M.: Preexisting bone loss associated with ovariectomy in rats is reversed by parathyroid hormone. J. Bone Miner. Res. 6: 1071-1080, 1991.
46. Slovik D.M., Neer R.M., Potts J.T.: Short-term effects of synthetic human parathyroid hormone-(1-34) administration on bone mineral metabolism in osteoporotic patients. J. Clin. Invest. 68. 1261-1271, 1981.
47. Reeve J., Hesp R., Williams D., Hulme P., Klenerman L : Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis. Lancet 1: 1035-1038, 1976.
48. Reeve J., Tragear G.W., Parsons J.A.: Preliminary trial of low doses of human parathyroid hormone 1-34 peptide in treatment of osteoporosis. Calcif. Tissue Res. 21: 469-477, 1976.
49. Reeve J., Meunier P.J., Parsons J.A., Bemat M., Bijvoet O.L., Courpron P , Edouard C., Klenerman L., Neer R.M., Renier J.C., Slovik D., Vismans F.J., Potts J.T.: Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial BMJ 280: 1340-1344, 1980.
50. Slovik D.M., Rosenthal D.I., Dopplet S.U., Potts J.T., Daly M.A., Campbell J.A., Neer R.M.: Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D. J. Bone Miner. Res. 1: 377-381, 1986.
51. Neer M , Slovik D., Daly N., Potts J.T., Nussbaum S.R.: Treatment of postmenopausal osteoporosis with daily parathyroid hormone plus calcitriol Osteoporos. Int. 1: 204-205, 1993.
52. Finkelstein J.S., Kiblanski A., Schaefer E.H., Homstein M.D., Schiff I., Neer R.M.: Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N. Engl. J. Med. 331: 1618-1623, 1994.
53. Reeve J., Arlot M.E., Bradbeer J.N., Human parathyroid peptide treatment in treatment of osteoporosis. Osteoporos. Int. 3: S199-203, 1993.
54. Hesch R.D., Busch U., Prokop M., Delling G., Ritinghaus E F.: Increase in vertebral density by combination therapy with pulsatile 1-38 PTH and sequential addition of calcitonin nasal spray in osteoporotic patients. Calcif. Tissue Int. 44: 176-180, 1989.
55. Hodsman A.B., Steer B.M., Fraher L.J., Drost D.J.: Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients. Bone Miner. 14: 67-83, 1991
56. Hodsman A.B , Fraher L.J.: Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients. Bone Miner. 9: 137-152, 1990.
57. Hodsman A.B., Fraher L.J., Ostbye T., Adachi J.D., Steer B.M.: An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. J. Clin. Invest. 91:1138-1148, 1993.
58. Hodsman A.B., Fraher L.J., Watson P.H., Ostbye T., Stitt L.W., Adachi J.D., Taves D.H., Drost D.: A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J. Clin. Endocrinol. Metab. 82: 620-628, 1997.
59. Hesch R.D., Heck J., Delling G., Keck E., Reeve J., Canzler H., Schober O., Harms H., Rittinghaus E.F.: Results of stimulatory therapy of low bone metabolism in osteoporosis with (1-38) hPTH and diphosphonate EHDP. Klin. Wochenschr 66: 976-984, 1988.
60. Lindsay R., Nieves J., Formica C., Henneman E., Woelfert L., Shen V., Dempster D., Cosman F.: Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350: 550-555, 1997.
61. Cosman F., Nieves J., Woelfert L., Gordon S., Shen V., Lindsay R : Parathyroid responsivity in postmenopausal women with osteoporosis during treatment with parathyroid hormone. J. Clin. Endocrinol. Metab. 83: 788-790, 1998.